Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
point-mutated feline HER2 DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Wayne State University
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The point-mutated feline HER2 DNA vaccine (also known as pfeHER2-K or feHER2-K) is a research-stage veterinary DNA vaccine designed to overcome immune tolerance to the HER2 self-antigen in cats. It consists of a plasmid DNA construct encoding a feline HER2 protein with a single amino acid point mutation (specifically the Q141K substitution), which introduces a positive charge on an exposed surface region. This modification renders the self-antigen sufficiently foreign to break immune tolerance and stimulate both humoral and cellular immune responses while preserving the overall HER2 protein structure and epitopes. Administered via intramuscular electrovaccination (DNA electroporation), the vaccine is being investigated for the treatment of feline mammary carcinoma (FMC), a spontaneous cancer in domestic cats that closely mirrors HER2-positive human breast cancer.
- Other names
- feline HER2 Q141K DNA vaccinefeline HER2-K DNA vaccinepoint-mutated feline HER2 vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on point-mutated feline HER2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on point-mutated feline HER2 DNA vaccine.